Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -861.33% is 1261% below its 5-year average of -63.27%, near the low end of its 5-year range (-1145.87%–0.00%).
258.23% below its 12-month average of -240.44%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -270.93%.
OPERATING MARGIN
-861.33%
OPERATING MARGIN AVG TTM
-240.44%
OPERATING MARGIN AVG 3Y
-109.29%
OPERATING MARGIN AVG 5Y
-63.27%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-258.23%
CURRENT VS 3Y AVG
-688.12%
CURRENT VS 5Y AVG
-1261.29%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 786 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Prelude Therapeutics Incorporated
Market Cap
$213.21M
Operating Margin
-861.33%
TTM Avg
-240.44%
3Y Avg
-109.29%
5Y Avg
-63.27%
Market Cap
$213.44M
Operating Margin
6.67%
TTM Avg
9.41%
3Y Avg
-3.44%
5Y Avg
-14.56%
Market Cap
$211.48M
Operating Margin
-692.83%
TTM Avg
-418.51%
3Y Avg
-274.13%
5Y Avg
-339.94%
Market Cap
$211.33M
Operating Margin
40.94%
TTM Avg
-5.20%
3Y Avg
-130.22%
5Y Avg
-446.71%
Market Cap
$216.34M
Operating Margin
66.70%
TTM Avg
45.54%
3Y Avg
40.90%
5Y Avg
43.81%
Market Cap
$208.32M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$207.98M
Operating Margin
-3099.93%
TTM Avg
-1606.37%
3Y Avg
-882.98%
5Y Avg
-646.62%
Market Cap
$206.06M
Operating Margin
16.75%
TTM Avg
16.40%
3Y Avg
14.66%
5Y Avg
13.83%
Market Cap
$206.61M
Operating Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $213.21M | -861.33% | -240.44% | -109.29% | -63.27% |
| Niagen Bioscience Inc (NAGE)vs › | $213.44M | 6.67% | 9.41% | -3.44% | -14.56% |
| Alector, Inc. (ALEC)vs › | $211.48M | -692.83% | -418.51% | -274.13% | -339.94% |
| Compugen Ltd. (CGEN)vs › | $211.33M | 40.94% | -5.20% | -130.22% | -446.71% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.34M | 66.70% | 45.54% | 40.90% | 43.81% |
| Sionna Therapeutics, Inc. (SION)vs › | $208.32M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $207.98M | -3099.93% | -1606.37% | -882.98% | -646.62% |
| Pro-Dex, Inc. (PDEX)vs › | $206.06M | 16.75% | 16.40% | 14.66% | 13.83% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $220.74M | -566038.89% | -577080.92% | -336097.22% | -224856.35% |
Gross Margin
85.9%
Operating Margin
-861.3%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -270.93% |
| 2026-03-31 | -309.54% |
| 2025-12-31 | -307.59% |
| 2025-09-30 | -314.12% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | -845.78% |
| 2024-09-30 | -1145.87% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
